Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec;4(24):531.
doi: 10.21037/atm.2016.11.58.

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention

Pradeep Karur  1 , Dave Singh  1
Affiliations
Comment

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention

Pradeep Karur et al. Ann Transl Med. 2016 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

D Singh has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Glenmark, Merck, NAPP, Novartis, Pfizer, Respivert, Skypharma, Takeda, Teva, Therevance and Verona. And other author has no conflicts of interest to declare.

Comment on

  • Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
    Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Clinical Trial.

References

    1. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398S-401S. 10.1378/chest.117.5_suppl_2.398S - DOI - PubMed
    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38. 10.1056/NEJMoa0909883 - DOI - PubMed
    1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65. 10.1164/rccm.201204-0596PP - DOI - PubMed
    1. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26. 10.1164/rccm.200707-973OC - DOI - PubMed
    1. Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol 2015;79:695-708. 10.1111/bcp.12545 - DOI - PMC - PubMed

LinkOut - more resources